---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-093153"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:13:37.467205+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics pays $14.8M to terminate Cambridge sublease with Novartis

## Summary
- One-time termination payment of $14,780,188 to Novartis for early exit from 69,000 sq ft sublease.
- Sublease originally scheduled to end Feb 2028 or earlier; terminated effective March 31, 2023.
- Principal executive offices moving to 300 Technology Square, Cambridge, MA.
- Sublease covered R&D, laboratory, and office space at 100 Technology Square.

## SEC filing metadata
- accession: 0001193125-23-093153
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/0001193125-23-093153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/d488935d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-093153
- JSON: https://secwatch.observer/filing/0001193125-23-093153.json
- Plain text: https://secwatch.observer/filing/0001193125-23-093153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.